Carvedilol
Product Images NDC 66116-429

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 66116-429). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medvantx, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula For Carvedilol (40a98410 9568 4278 959e Ca3517a9b119 01)

Chemical structure of Carvedilol, depicting its molecular arrangement with characteristic functional groups including hydroxyl, methoxy, and amine groups attached to the bicyclic core structure.*

FDA Label Image

Figure 1 (40a98410 9568 4278 959e Ca3517a9b119 02)

A line graph comparing the percentage of mortality over 21 months between Carvedilol and placebo groups. The x-axis represents time in months, and the y-axis shows percent mortality. The Carvedilol group has a lower mortality percentage compared to the placebo group across the time period shown, with a p-value of 0.0014 indicated on the graph.*

FDA Label Image

Figure 2 (40a98410 9568 4278 959e Ca3517a9b119 03)

A forest plot chart depicting hazard ratios for various subgroups of patients including men, women, age groups, racial groups, diabetic status, ischemic status, heart rate, systolic blood pressure, and spironolactone use, with confidence intervals shown for each group around a central vertical line at hazard ratio of 1.0.*

FDA Label Image

Figure 3. Survival Analysis For Capricorn (intent-to-treat) (40a98410 9568 4278 959e Ca3517a9b119 04)

A survival curve chart depicting percentage mortality over a 24-month period comparing Carvedilol and placebo groups. The y-axis represents percent mortality from 0 to 30%, and the x-axis represents months from 0 to 24. The graph shows that mortality rises more slowly in the Carvedilol group than in the placebo group, with a p-value of 0.03 indicated.*

FDA Label Image

Figure 4. Effects On Mortality For Subgroups In Capricorn (40a98410 9568 4278 959e Ca3517a9b119 05)

Forest plots depicting hazard ratios with confidence intervals for various subgroups in a clinical study. Subgroups include age, gender, timing of randomization post-myocardial infarction, prior intravenous or oral beta-blocker use, Killip classes, thrombolytic therapy, percutaneous transluminal coronary angioplasty status, history of congestive heart failure, use of diuretics during myocardial infarction, presence of angina, hypertension, diabetes, heart rate, and systolic blood pressure. Each subgroup's hazard ratio is plotted with a reference line at 1.0, indicating no effect.*

FDA Label Image

Carvedilol 12.5mg Tablets #60 (40a98410 9568 4278 959e Ca3517a9b119 06)

Carvedilol Tablets, USP 12.5 mg bottle label showing 60 tablets. Label indicates the manufacturer as Teva Pharmaceuticals Ind. Ltd., Jerusalem, Israel, and distributed by MedVantx, Inc., San Diego, CA. Includes storage instructions and a note that the product is for prescription use only and sample use, not for sale.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.